文献速递肾小球疾病

IgA肾病激素反应性的遗传决定因素

Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2025-12-11

基于TESTING研究260例活检确诊IgA肾病患者的全基因组药物基因组学分析,发现rs477155(CDA内含子变异)与糖皮质激素反应相关,并在211例独立队列中复制。rs477155 GG基因型患者6个月完全蛋白尿缓解和复合临床缓解率显著更高,功能分析提示NR3C1可能直接调控CDA表达。

要点

  • rs477155 GG基因型与IgA肾病患者糖皮质激素诱导的蛋白尿缓解率更高相关。
  • rs477155可能通过糖皮质激素受体NR3C1调控CDA表达,影响激素敏感性。
  • 该变异或有助于识别可从激素治疗中获益的IgA肾病患者。

核心结论

  • rs477155与IgA肾病糖皮质激素反应性存在提示性关联,可能通过NR3C1调控CDA通路介导。

研究设计与样本

  • 在TESTING研究260例活检确诊IgA肾病患者(134例甲泼尼龙,126例安慰剂)中进行全基因组药物基因组学分析,以6个月24小时蛋白尿下降百分比为结局。
  • 在211例接受糖皮质激素单药治疗的高危患者独立队列中进行复制。
  • 采用功能注释、表达数量性状位点定位、调控分析和双荧光素酶报告基因实验探究候选位点的生物学相关性。

主要发现

  • 全基因组分析识别出3个提示性基因型-治疗交互位点(P < 5.00×10^-6),其中rs477155(1号染色体,CDA内含子)在独立队列中复制(发现P = 2.70×10^-6,复制P = 0.01)。
  • TESTING队列中,rs477155 GG基因型携带者6个月完全蛋白尿缓解率显著更高(OR 2.5,95%CI 1.3–4.9,P = 5.00×10^-3),复合临床缓解率也显著更高(OR 2.8,95%CI 1.6–4.9,P = 3.13×10^-4)。
  • 功能分析显示rs477155是血液和免疫细胞中CDA的顺式表达数量性状位点,位于H3K4Me1/H3K27Ac标记的增强子区域及NR3C1结合位点内。
  • 生物信息学、双荧光素酶报告基因实验和RNA-seq分析提示NR3C1可能直接调控CDA表达,地塞米松刺激后血液中CDA快速上调(9.84±0.52 vs 10.50±0.55,P = 7.41×10^-23)。
  • 全表型组关联研究将rs477155和CDA与多种免疫和肾脏性状关联,包括急性肾小管间质性肾炎(P = 7.4×10^-11)、肾炎综合征(P = 2.7×10^-8)、哮喘(P = 2.5×10^-21)和类风湿关节炎(P = 2.1×10^-12)。

临床怎么用

  • rs477155 GG基因型可能作为IgA肾病患者糖皮质激素反应性的遗传标记,辅助个体化治疗决策。
  • 该发现尚需进一步验证,暂不建议常规基因检测指导激素治疗。

局限性

  • rs477155与激素反应性的关联为提示性(suggestive),未达到全基因组显著性阈值。
  • 功能分析提示NR3C1调控CDA通路,但未直接证实因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Genetic variant rs477155 near cytidine deaminase identified IgA nephropathy patients with enhanced glucocorticoid response. rs477155 may regulate cytidine deaminase via glucocorticoid receptor, linking genomic variation to steroid sensitivity and individualized treatment optimization. BACKGROUND: Glucocorticoid therapy improves outcomes in high-risk IgA nephropathy but shows variable efficacy and adverse effects, potentially influenced by genetic factors. METHODS: We conducted a genome-wide pharmacogenomic analysis in 260 biopsy-confirmed patients with IgA nephropathy from the Chinese The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study cohort (134 received methylprednisolone and 126 received placebo), assessing the percentage reduction in 24-hour proteinuria at 6 months via genotype-by-treatment interaction models. Replication was performed in an independent cohort of 211 high-risk patients receiving glucocorticoid monotherapy. Functional annotation, expression quantitative trait loci mapping, regulatory analyses, and dual-luciferase reporter assays elucidated the biologic relevance of candidate loci. RESULTS: Genome-wide analysis identified three loci with suggestive genotype-by-treatment interaction ( P < 5.00×10 -6 ), of which rs477155 (chromosome 1, intronic to cytidine deaminase [ CDA ]) was replicated in the independent cohort (discovery P = 2.70×10 -6 , replication P = 0.01). In the TESTING study cohort, carriers of the rs477155 GG genotype had significantly higher rates of complete proteinuria remission (odds ratio, 2.5; 95% confidence interval, 1.3 to 4.9; P = 5.00×10 -3 ) and composite clinical remission (odds ratio, 2.8; 95% confidence interval, 1.6 to 4.9; P = 3.13×10 -4 ) at 6 months. Functional analyses revealed that rs477155 acts as a Cis -expression quantitative trait locus for CDA in blood and immune cells and is located within an enhancer region marked by H3K4Me1/H3K27Ac and a glucocorticoid receptor (nuclear receptor subfamily 3 group C member 1 [NR3C1])-binding site. Bioinformatics, dual-luciferase reporter assay, and RNA-seq analyses indicated that NR3C1 may directly regulate CDA expression, with rapid upregulation of CDA observed in blood after dexamethasone stimulation (9.84±0.52 versus 10.50±0.55, P = 7.41×10 -23 ). Phenome-wide association studies further linked rs477155 and CDA to a spectrum of immune and kidney traits, including acute tubulointerstitial nephritis ( P = 7.4×10 -11 ), nephritic syndrome ( P = 2.7×10 -8 ), asthma ( P = 2.5×10 -21 ), and rheumatoid arthritis ( P = 2.1×10 -12 ). CONCLUSIONS: In this study, rs477155 was suggestively associated with glucocorticoid responsiveness in IgA nephropathy, potentially via a suggested NR3C1-regulated CDA pathway.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Xu LL, Zhou XJ, Bi W, et al. Genetic Determinants of Steroid Responsiveness in IgA Nephropathy. J Am Soc Nephrol. 2025. PMID: 41563292. doi:10.1681/ASN.0000000977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。